GET DAILY SIGNALSCytoMed Therapeutics (GDTC) Down 7% Over 30 Days as Clinical Work Advances
Key Takeaways
- CytoMed Therapeutics (GDTC) is a Singapore-based clinical-stage biopharmaceutical company developing "off-the-shelf," donor-derived cell therapies for blood and solid cancers.
- Shares have declined roughly 7% over the trailing 30 days, trading near $0.86, well below the 52-week high of $2.29 and not far from the 52-week low near $0.68.
- The lead candidate, CTM-N2D, is advancing through a first-in-human Phase I trial (ANGELICA) at National University Hospital Singapore, with trial completion targeted for 2026.
- With a market capitalization around $10 million, GDTC is a micro-cap with heavy insider ownership (roughly 70%) and minimal institutional participation, leaving the stock sensitive to clinical news and funding developments.
- The company reported a wider fiscal 2025 net loss and lower cash reserves, underscoring the execution and financing risks common to early-stage biotechs.
- Explore additional details on GDTC's Price Targets, Earnings, and Forecast to support your own research.
Market Position and Recent Performance
CytoMed Therapeutics trades near $0.86 after falling about 7% over the past month from levels near $0.93. The stock sits in micro-cap territory with a market capitalization of roughly $10 million, and trading volume remains modest, which tends to magnify moves on limited flow.
Shares trade well below the 52-week high of $2.29 and closer to the low end near $0.68. Insiders hold around 70% of the shares, while institutions account for just 0.3%, so the float is limited and sentiment can shift on clinical updates or financing news. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
CytoMed’s Business and Approach to Cell Therapies
Founded in 2018 as a spin-off from Singapore’s Agency for Science, Technology and Research (A*STAR), CytoMed focuses on allogeneic, donor-derived cell immunotherapies. These are positioned as more scalable and potentially lower-cost than autologous CAR-T therapies that rely on a patient’s own cells.
The lead program, CTM-N2D, engineers gamma delta T cells to target NKG2D ligands on cancer cells. It requires no donor-patient matching and is under evaluation in the ANGELICA Phase I trial for advanced solid and blood cancers. The pipeline also includes unmodified gamma delta T cells (CTM-GDT), iPSC-derived candidates, and CTM-MSC for cartilage applications, plus work through the LongevityBank subsidiary on cord blood natural killer cells.
Recent Clinical and Financial Updates
Progress on the ANGELICA trial remains central. Dose level 1 is complete, dose level 2 is underway with six patients treated so far, and escalation continues toward the highest planned dose. Management continues to target full trial completion in 2026. A December 2025 memorandum of understanding with Universiti Malaya supports plans for a Phase I study of CTM-GDT in Malaysia, with an IND filing expected before mid-2026.
Fiscal 2025 results showed revenue and other income near $0.78 million alongside a widened net loss of about $3.1 million. Cash stood at $1.63 million, down from $3.87 million a year earlier. These numbers underscore the funding needs typical for early-stage oncology companies. Preclinical work with MD Anderson Cancer Center on CTM-GDT in acute myeloid leukemia has also been noted, and the latest analyst view was a Sell rating with a $0.81 target.
What to Watch in 2026
Key catalysts center on clinical data readouts from ANGELICA, any movement toward Phase II, and advancement of the Malaysia trial for CTM-GDT. Updates from the MD Anderson collaboration and LongevityBank program could further shape the story.
From a financial standpoint, cash runway, potential new financing, and research spending will stay in focus given the limited balance sheet. As with most early-stage developers in oncology, outcomes hinge on hitting trial milestones while managing dilution risk.
Using Tickeron AI Tools for Ongoing Monitoring
I regularly review Tickeron’s Trending AI Robots to see how quantitative strategies are performing across similar micro-cap names. The platform highlights top bots with different timeframes and metrics, which helps me cross-check my own views on names like GDTC without replacing fundamental analysis. This approach adds another layer when scanning for signals in a volatile sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for GDTC turns negative, indicating new downward trend
GDTC saw its Momentum Indicator move below the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 77 similar instances where the indicator turned negative. In 71 of the 77 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for GDTC turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 37 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
GDTC moved below its 50-day moving average on November 04, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GDTC crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GDTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +0.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where GDTC advanced for three days, in 115 of 135 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
GDTC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. GDTC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.139) is normal, around the industry mean (3.498). P/E Ratio (0.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (36.765) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GDTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology